Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care in Japanese Patients (Pegylated-interferon Alpha-2a and Ribavirin)
Launched by BRISTOL-MYERS SQUIBB · Nov 19, 2009
Trial Information
Current as of June 06, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Key Inclusion Criteria:
- • Subjects chronically infected with hepatitis C virus (HCV) genotype 1
- • HCV RNA viral load ≥ 10\*5\* IU/mL (100,000 IU/mL) at screening
- • The current standard of care naïve or non-responder
- Key Exclusion Criteria:
- • Cirrhosis
- • HCC
- • Co-infection with hepatitis B virus (HBV), HIV-1 or HIV-2
About Bristol Myers Squibb
Bristol-Myers Squibb (BMS) is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. With a robust portfolio of products across multiple therapeutic areas, including oncology, immunology, cardiovascular, and fibrotic diseases, BMS emphasizes cutting-edge research and a commitment to advancing medical science through clinical trials. The company is driven by a mission to provide transformative therapies, leveraging collaboration and scientific expertise to address unmet medical needs and improve patient outcomes worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chiba Shi, Chiba, Japan
Okayama Shi, Okayama, Japan
Osaka Shi, Osaka, Japan
Musashino Shi, Tokyo, Japan
Kurume Shi, Fukuoka, Japan
Patients applied
Trial Officials
Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials